Novo Nordisk stock trades near record levels as Ozempic and Wegovy drive double digit growth

Novo Nordisk stock is trading close to record territory, supported by strong demand for its GLP-1 diabetes and obesity treatments and robust recent financial results. The Danish pharmaceutical group Novo Nordisk A/S (ISIN DK0062498333) has reported double digit revenue and operating profit growth in its latest full year and interim figures, underpinned by rapid uptake of Ozempic and Wegovy in major markets as of 2024 and 2025. For investors, the balance between supply expansion, pricing dynamics and long term obesity treatment penetration now matters most.

Revenue up double digits

According to Novo Nordisk's 2024 annual report and investor communications, the company delivered strong top line expansion, with reported revenue for the 2024 financial year rising by more than ten percent compared with 2023, driven primarily by GLP-1 medicines for diabetes and obesity. In North America, revenue growth was even faster, with sales in the region increasing by a double digit percentage in 2024 versus 2023 as Ozempic and Wegovy volumes climbed and higher value formulations gained share. The company has highlighted that the obesity care segment alone contributed several billion dollars of revenue in 2024, up significantly from the prior year as more patients initiated treatment and coverage expanded.

Operating profit also increased at a double digit rate in 2024 compared with 2023, reflecting both strong volume growth and disciplined cost control. Novo Nordisk's reported operating margin remained high by global pharma standards, with management pointing to continued investment in manufacturing capacity, research and development and commercial infrastructure, particularly in obesity and cardiometabolic care. Net profit for 2024 likewise rose by a substantial amount versus 2023, as the higher revenue base and favorable product mix more than offset increased expenditure related to supply expansion and clinical programs.

GLP-1 therapies expand globally

Novo Nordisk's GLP-1 products, including Ozempic for type 2 diabetes and Wegovy for obesity, have been central to its growth story. In 2024, GLP-1 based therapies accounted for a large share of the company's total sales, and demand continued to outstrip previous expectations. Prescription volumes for Wegovy rose sharply year on year, with obesity care revenue increasing by a sizeable percentage compared with 2023, underscoring the scale of unmet need in weight management and cardiometabolic risk reduction. Ozempic also maintained strong momentum, with global diabetes care sales growing at a healthy rate thanks to new patient starts and switches from older therapies.

The company has responded to this demand by investing heavily in manufacturing capacity. Novo Nordisk has committed billions of dollars over multiple years to expand production facilities in Denmark and internationally, aiming to secure long term supply for GLP-1 injectables and potential future oral formulations. These investments contribute to the capital expenditure line in the financial statements and are expected to support revenue growth over the coming decade. For investors, the pace at which new capacity comes online is a key factor in assessing how much further GLP-1 revenue can grow without running into persistent supply constraints.

Obesity care revenue jumps over prior year

Obesity care is one of Novo Nordisk's fastest growing segments. In its recent reporting for 2024, the company indicated that obesity care revenue increased by a substantial double digit percentage compared with 2023, reflecting growing recognition of obesity as a chronic disease and wider access to pharmacologic treatment. The Wegovy brand has been launched in several major markets, including the United States and parts of Europe, with each launch contributing to segment growth. This quantified year on year increase in obesity revenue highlights how the franchise is shifting Novo Nordisk's overall revenue mix toward weight management and cardiometabolic risk reduction, beyond traditional diabetes care alone.

At the same time, management has acknowledged that payer policies, reimbursement criteria and long term adherence will shape the sustainable size of the obesity treatment market. Current guidance for 2025 and 2026 assumes continued strong growth in obesity care, but with moderation from the initial launch acceleration as the market matures. This guidance implies that obesity care revenue could again rise meaningfully versus prior years, though the exact percentages will depend on market specific decisions by public health systems and private insurers. For investors, the quantified growth in this segment versus 2023 provides a reference point for evaluating whether future quarters meet, exceed or fall short of management's expectations.

Margin, cash flow and investment

Novo Nordisk's profitability metrics remain important to understanding Novo Nordisk stock's valuation. In 2024, the company reported a high operating margin, demonstrating that the revenue expansion from GLP-1 medicines translates into significant cash generation even after heavy investment in capacity and research. Free cash flow was strong, supporting dividend payments and share repurchases. Over the 2024 financial year, Novo Nordisk returned several billion dollars to shareholders via dividends and buybacks, while still funding organic growth initiatives.

Debt levels remained manageable, with the company maintaining a solid balance sheet and investment grade credit profile. Net debt was relatively low compared with annual EBITDA, giving Novo Nordisk flexibility to continue investing in new production lines, clinical trials and potential business development opportunities. The combination of double digit revenue growth, high margins and disciplined capital allocation contributes to the premium valuation often assigned to Novo Nordisk stock relative to many other large pharmaceutical companies.

Competition and consensus context

In assessing Novo Nordisk stock, many investors compare the company's GLP-1 portfolio with that of peers in the obesity and diabetes space. While direct competitor names vary by market, the overall landscape includes several major pharmaceutical companies developing or marketing GLP-1 analogues and related therapies. Consensus estimates for Novo Nordisk's revenue and earnings growth over the next few years generally assume that GLP-1 demand remains strong and that the company sustains high margins, though analysts also model potential pricing pressures and competition from alternative modes of therapy.

Recent analyst consensus figures, as reflected in compiled market data for 2025 and 2026, typically forecast ongoing double digit growth in earnings per share over the medium term, compared with the already strong performance in 2024. This comparison between future estimates and past reported results helps investors gauge whether the current stock price and valuation multiples embed realistic expectations or require further upside in performance to be justified. Novo Nordisk's ability to deliver revenue and profit ahead of consensus in previous periods has contributed to the positive sentiment surrounding the stock.

Ozempic drives diabetes care growth

Ozempic, Novo Nordisk's once weekly GLP-1 injection for type 2 diabetes, is a flagship product in the diabetes care portfolio. In the latest full year reporting, diabetes care revenue increased by a significant double digit percentage compared with 2023, with Ozempic accounting for a large share of that growth. The product has gained traction among physicians and patients because of its efficacy in blood glucose control, weight reduction and cardiovascular risk profile, as demonstrated in clinical trials. This performance supports Novo Nordisk stock by providing a stable and growing base in traditional diabetes treatment, complemented by the newer obesity care line.

Ozempic's success has also prompted ongoing research into additional indications and potential oral formulations. Novo Nordisk is investing in clinical trials that extend GLP-1 use into broader cardiometabolic conditions, which could further expand the addressable market. The diabetes care segment's quantified growth versus 2023 sets a reference point for future evaluations of whether new indications and geographies deliver incremental revenue over and above the strong base established in 2024.

Wegovy underpins obesity strategy

Wegovy, Novo Nordisk's obesity treatment based on semaglutide, plays a central role in the company's long term strategy. In 2024, obesity care revenue rose sharply compared with 2023, driven largely by Wegovy. The company has reported that the obesity care segment grew at a double digit rate, with Wegovy prescriptions increasing across launching markets. This quantified comparison with the prior year showcases the rapid expansion of pharmacologic obesity management and positions Novo Nordisk as a leading player in this therapeutic area.

Supply constraints have been a recurring theme as demand outpaced initial expectations. To address this, Novo Nordisk has announced multiple manufacturing expansion projects, including new facilities and upgrades to existing plants, with capital expenditure commitments running into billions of dollars over several years. These investments are reflected in higher capital spending figures in 2024 and planned for 2025, compared with earlier years when GLP-1 demand was lower. For investors, the relationship between these spending figures and future revenue growth is critical to understanding the medium term trajectory of Novo Nordisk stock.

Shares supported by strong fundamentals

Novo Nordisk stock trades on the primary listing in Denmark and via depositary receipts in other markets, with a market capitalization in 2024 ranking among the largest global pharmaceutical companies. The stock price has moved higher over recent years as revenue, profit and cash flow have increased, with the market responding positively to the quantified growth in GLP-1 sales and obesity care. As of late 2024, Novo Nordisk shares were near their 52-week high, illustrating how financial performance and investor expectations have converged at elevated levels.

Valuation metrics such as the price to earnings ratio and enterprise value to EBITDA reflect the premium attached to Novo Nordisk's growth profile. Compared with many peers, the company trades at higher multiples, justified by the strong historical growth and projected future expansion in GLP-1 markets. The quantified year on year increases in revenue and operating profit for 2024 support this valuation, though investors also remain attentive to potential risks, including competition, regulatory scrutiny and evolving payer policies.

Representative product: Ozempic

Ozempic stands out as a representative product in Novo Nordisk's portfolio and illustrates how innovation feeds through to Novo Nordisk stock performance. The GLP-1 injection generates a large part of the company's diabetes care revenue and has helped drive double digit growth in that segment from 2023 to 2024. Clinical data show substantial reductions in HbA1c and body weight, which have underpinned its adoption in treatment guidelines and everyday practice. As Ozempic revenue continues to rise, it supports the company's ability to invest in future products and capacity expansion, reinforcing the growth story that investors see reflected in the stock price.

Novo Nordisk stock price context

Novo Nordisk stock is traded primarily on the Nasdaq Copenhagen exchange, where it has seen its price trend upward over recent financial years, in line with rising revenue, profit and cash flow. As of late 2024, the shares were near their 52-week high, with a market capitalization in the hundreds of billions of dollars equivalent. This price context reflects the markets response to the company's double digit growth in 2024 compared with 2023 and expectations for continued expansion in 2025 and beyond. The stock price level, together with the quantified financial metrics, provides a framework for investors assessing Novo Nordisk's role in diversified healthcare and growth portfolios.